Trial · NCT06772064
Efficacy of Rifaximin in Patients With Small Intestinal Bacterial Overgrowth Presenting With Abdominal Bloating.
NCT06772064, Not applicable, Recruiting, Xiuli Zuo
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy of Rifaximin in Patients With Small Intestinal Bacterial Overgrowth Presenting With Abdominal Bloating. Trials, record NCT06772064. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06772064
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy of Rifaximin in Patients With Small Intestinal Bacterial Overgrowth Presenting With Abdominal Bloating.
- NCT number
- NCT06772064
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 115 participants, estimated
- Lead sponsor
- Xiuli Zuo
- Conditions
- SIBO
- Interventions
- Rifaximin (drug)
- First posted
- 2025-01-13
- Last updated
- 2025-05-16
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Negative conversion rate of hydrogen and methane breath testing | Up to 1 week after hydrogen and methane breath testing | Negative conversion rate of hydrogen and methane breath testing in patients treated with rifaximin. |
| Secondary | Symptom remission rate | During the administration period, 1 month after the end of the administration, 3 months and 6 months of follow-up | Symptom remission rate in patients treated with rifaximin |
| Other | Changes of fecal flora (16 S Sequence Analysis). | Immediately collect fecal before and after taking rifaximin. | Changes of fecal flora before and after rifaximin administration. |
| Other | The difference of fecal flora between patients and normal population (16 S Sequence Analysis). | Test immediately after collection of stool sample. | |
| Other | Psychopsychological questionnaire score | Collect the questionnaire and rate it immediately. | Self-rating depression scale (SDS): minimum value: 20; maximum value:100;The dividing line between normal and anxious patients is 50 points, with higher scores indicating more severe anxiety. Self-Rating Anxiety Scale (SAS): minimum value: 20; maximum value:100; In the Chinese population, the dividing line between normal and depressed people is 53 points, with higher scores indicating more severe depression. Hamilton Anxiety Scale (HAMA):minimum value: 0; maximum value:56; The dividing line between normal and anxious patients is 7 points, with higher scores indicating more severe anxiety. Hamilton Depression Scale (HAMD): minimum value: 0; maximum value: 96; the dividing line between normal and depressed people is 8 points, with higher scores indicating more severe depression. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06772064
GET https://conductscience.org/api/trials/v1/NCT06772064/registered